Our laboratory utilizes DNA sequencing, gene expression profiling, proteomic analyses, flow cytometric methodology and many other basic techniques to pursue goals that are ultimately translatable for improving health and overall survival in patients with brain cancer. Although our research is primarily focused on malignant glioma, with a special emphasis on glioblastoma, we are also interested in pursuing incurable pediatric brain tumors, as well as metastatic tumors that invade the brain/spinal cord. It is our sincere hope
News & Events
Congratulations to Senior Postdocs. Drs. Lijie Zhai and Erik Ladomersky from our laboratory for being selected to attend the Society for Neuro-Oncology Young Investigator’s Forum!
The Wainwright Laboratory welcomes first-year Driskill Graduate Program student Corey Dussold, who has chosen to perform his PhD dissertation work with our group. Welcome aboard, Corey!
Members of the Wainwright Laboratory team recently attended the Malnati Brain Tumor Institute Gala sponsored by the GBM Foundation. Thank you for your support!
Dr. Wainwright returns from UCLA after honoring a leader, in memoriam, of brain cancer immunology and immunotherapy. Thank you Dr. Carol Kruse, PhD, for everything that you founded in our field and beyond.
Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R. Newly diagnosed glioblastoma: a review on clinical management. 2019. Oncology Live. 33(3): 91-100. PMID: 30866031
Otto-Meyer S, Lumibao J, Kim E, Ladomersky E, Zhai L, Lauing KL, Scholtens DM, Penedo F, Amidei C, Lukas RV, Wainwright DA. The interplay among psychological distress, the immune system, and brain tumor patient outcomes. 2019. Current Opinion in Behavioral Sciences. 28: 44-50. PMID: 31049368
Ladomersky E, Scholtens DM, Kocherginsky M, Hibler EA, Bartom ET, Otto-Meyer S, Zhai L, Lauing KL, Choi J, Sosman JA, Wu JD, Zhang B, Lukas RV, Wainwright DA. The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma. 2019. Frontiers in Pharmacology. 10: 200. PMID: 30971917
Zhai L, Ladomersky E, Lauing KL, Wu M, Scholtens DM, Savoor R, Zhang B, Wu JD, Horbinski C, Lukas RV, Binder DC, Wainwright DA. 2018. Commentary: preclinical efficacy of immune checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). Oncoimmunology. 8(3): 1548242. PMID: 30723577
Binder DC, Ladomersky E, Lenzen A, Zhai L, Lauing KL, Otto-Meyer SD, Lukas RV, Wainwright DA. 2018. Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. Translational Cancer Research. 7(Suppl 4):S510-S513. PMID: 30283731.
Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang Z, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA. 2018. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clinical Cancer Research. 24(11):2559-2573. PMID: 29500275